PCDHB6

Across TCGA pan-cancer cohorts, PCDHB6 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PCDHB6 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher PCDHB6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PCDHB6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and OV are the cancer types where PCDHB6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	II,III,IV	0.880	0.296	.004	22	view →
OV	DFS	Median	II,III,IV	0.218	0.543	.009	18	view →
HNSC	DFS	Median	II,III,IV	0.176	0.562	.007	9	view →
UCS	DFS	Median	All	0.132	0.530	.041	6	view →
ESCA	OS	Median	III,IV	0.238	0.580	.012	6	view →
SKCM	OS	Median	III,IV	0.615	0.860	.004	5	view →
LIHC	OS	Median	All	0.480	0.779	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PCDHB6–THYM (OS)

Open the THYM breakdown →